Patients from 22+ countriesPlan your visit →
lutetium-therapy
Blog

Latest from research and the clinic.

New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.

Medically reviewedUpdated 14 Nov 2024
Considering Lu-177 Therapy5 Sept 2026

PRRT for High-Grade GEP-NETs: Is Lu-177 DOTATATE Still an Option?

A Grade 3 GEP-NET diagnosis does not automatically rule out PRRT. Whether lutetium Lu-177 dotatate is still an option depends on whether your tumor expresses somatostatin receptors - and a Ga-68 DOTATATE PET scan is the key test.

8 min read
Comparing Options4 Sept 2026

When Somatostatin Analogues Are Enough for GEP-NET

If you have a GEP-NET and your oncologist has placed you on octreotide or lanreotide, you may wonder whether PRRT is also needed. For many patients with stable, slow-growing, well-differentiated tumors, somatostatin analogues may be the right treatment for now.

9 min read
Considering Lu-177 Therapy3 Sept 2026

Lu-177 PSMA Therapy After 75: What the Evidence Shows

There is no official upper age limit for Lu-177 PSMA therapy. What actually determines eligibility for older men with mCRPC is kidney function, bone marrow reserves, PSMA expression on a PET scan, and general fitness - not your age in years.

8 min read
Patient Journey2 Sept 2026

What to Expect in Your First Lu-177 PSMA Cycle

Your first Lu-177 PSMA therapy cycle involves more than just the infusion. This step-by-step guide covers what happens before, during, and after cycle one for men with PSMA-positive metastatic castration-resistant prostate cancer.

8 min read
Second Opinions1 Sept 2026

Lu-177 PSMA Second Opinion Before Your India Flight

If you are considering India for Lu-177 PSMA therapy, a remote eligibility review should come before any flight booking. This guide explains what a PSMA-PET second opinion covers, what documents to send, and what to expect if your results are borderline.

9 min read
Treatment Abroad1 Sept 2026

Is Lu-177 PSMA Therapy in India Worth the Travel Cost?

Lu-177 PSMA therapy in India costs a fraction of what the same treatment costs in the US or Germany. Here is what the savings look like, who actually qualifies, and when traveling makes sense - or does not.

8 min read
Treatment Abroad31 Aug 2026

Why NET Patients from Malaysia and Singapore Travel to India for PRRT

Patients with gastroenteropancreatic neuroendocrine tumours in Malaysia and Singapore are increasingly travelling to India for PRRT - peptide receptor radionuclide therapy with lutetium Lu-177 dotatate. This guide explains what drives that decision, what the treatment costs, and how to plan a practical path to care.

8 min read
Treatment Abroad31 Aug 2026

PRRT in India for GEP-NET Patients from Africa

If you have a GEP-NET and live in Nigeria, Kenya, or Ethiopia, Lu-177 DOTATATE PRRT is likely unavailable locally. This guide explains the access gap, what treatment in India costs compared to the United States, and how to arrange your care step by step.

10 min read
Considering Lu-177 Therapy29 Aug 2026

Lu-177 PSMA Therapy Does Not Work for Everyone

Lutetium Lu-177 PSMA therapy can extend survival in men with PSMA-positive mCRPC - but response is not guaranteed for everyone. This article looks at real VISION trial data, the reasons some patients do not respond, and what to discuss with your oncologist before you start.

9 min read
Second Opinions27 Aug 2026

Borderline PSMA-PET: Are You Eligible for Lu-177?

If your PSMA-PET scan came back 'borderline', your eligibility for lutetium Lu-177 vipivotide tetraxetan may not be a simple yes or no. This article explains what borderline positivity means, the criteria specialist teams actually use, and why a second expert read of your scan may change the answer.

8 min read
Patient Journey27 Aug 2026

What Happens During Your Lu-177 PSMA Infusion

If your first Lu-177 PSMA infusion is coming up, this step-by-step guide explains exactly what happens on the day - from blood checks and IV setup to radiation precautions before you go home.

8 min read
Considering Lu-177 Therapy27 Aug 2026

Reading PSA Trends During Lu-177 PSMA Therapy

Your PSA number during Lu-177 PSMA therapy tells part of the story - but only part. This guide explains what PSA50 response means, why an early rise is not always bad news, and how to read PSA trends alongside imaging.

8 min read

How we choose what to write about

We focus on three kinds of content:

  1. Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
  2. Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
  3. India updates - new centers, new approvals, new policies that affect Indian and India-bound patients

Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Blog - Page 2 - Lutetium Therapy Research, News, and Patient FAQs | lutetium-therapy